Trial · NCT01514201
Adverse events596
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 596
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Phase I, Dose Level 1 (50 mg/m2) | 4 | 6 | 11 |
| other | Anemia | Blood and lymphatic system disorders | Phase I, Dose Level 2 (65 mg/m2) | 4 | 6 | 20 |
| other | Anemia | Blood and lymphatic system disorders | Phase I, Dose Level 3 (85 mg/m2) | 6 | 6 | 13 |
| other | Anemia | Blood and lymphatic system disorders | Phase II (MTD) | 27 | 47 | 59 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase I, Dose Level 1 (50 mg/m2) | 0 | 6 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase I, Dose Level 2 (65 mg/m2) | 0 | 6 | 0 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase I, Dose Level 3 (85 mg/m2) | 1 | 6 | 1 |
| other | Febrile neutropenia | Blood and lymphatic system disorders | Phase II (MTD) | 0 | 47 | 0 |
| other | Palpitations | Cardiac disorders | Phase I, Dose Level 1 (50 mg/m2) | 1 | 6 | 1 |
| other | Palpitations | Cardiac disorders | Phase I, Dose Level 2 (65 mg/m2) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Phase I, Dose Level 3 (85 mg/m2) | 0 | 6 | 0 |
| other | Palpitations | Cardiac disorders | Phase II (MTD) | 0 | 47 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Phase I, Dose Level 1 (50 mg/m2) | 0 | 6 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Phase I, Dose Level 2 (65 mg/m2) | 1 | 6 | 1 |
| other | Sinus bradycardia | Cardiac disorders | Phase I, Dose Level 3 (85 mg/m2) | 0 | 6 | 0 |
| other | Sinus bradycardia | Cardiac disorders | Phase II (MTD) | 0 | 47 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I, Dose Level 1 (50 mg/m2) | 1 | 6 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Phase I, Dose Level 2 (65 mg/m2) | 0 | 6 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase I, Dose Level 3 (85 mg/m2) | 0 | 6 | 0 |
| other | Sinus tachycardia | Cardiac disorders | Phase II (MTD) | 0 | 47 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01514201/events